| Literature DB >> 35991582 |
Shrey Shah1, Chaitanya Karlapalem2, Pratik Patel1, Nikhil Madan1.
Abstract
Bacterial coinfections in patients infected with SARS-CoV-2 pneumonia are uncommon, when compared to coinfections with other respiratory viruses. For example, the prevalence of bacterial coinfections in hospitalized seasonal influenza patients can exceed 30%, whereas the prevalence of bacterial coinfections in SARS-CoV-2 infection is less than 4%. Bacterial coinfections increase the severity of respiratory viral infections and have been associated with higher mortality and morbidity. Current literature shows that diagnostic testing and antibiotic therapy for bacterial infections are not necessary upon admission in majority of patients with SARS-CoV-2 patients. It is however important for the clinician to be cognizant of these coinfections since missing the diagnosis may pose a substantial risk to vulnerable COVID-19 patients. In that light, we present four cases of Streptococcus pneumoniae coinfections complicating confirmed SARS-CoV-2 infections.Entities:
Year: 2022 PMID: 35991582 PMCID: PMC9391133 DOI: 10.1155/2022/8144942
Source DB: PubMed Journal: Case Rep Crit Care ISSN: 2090-6420
Figure 1CT scan: right lower lobe consolidation.
Figure 2Chest X-ray: bilateral consolidations.
Figure 3Chest X-ray: bilateral consolidations.
Figure 4CT scan: bilateral ground glass opacities.
Patient demographics and hospital stay details.
| Age | Sex | Past medical history | Symptoms on presentation | Lab findings | Radiological findings | Diagnosis of S. pneumoniae | Disposition | Treatment | Outcome | Hospital length of stay | ICU length of stay | Ventilator days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 51 | M | None | Shortness of breath | Hypoxemia 78% on RA, leukopenia 2200/mcl 4%lymphopenia, ferritin 3103 ng/mL, D-dimer 3.42 mg/L | CT-multifocal pneumonia | Urine antigen and blood cultures for S. pneumonia-positive | ICU complicated by VAP from ESBL and Klebsiella pneumoniae | Remdesivir, dexamethasone for COVID-19. Ceftriaxone for pneumonia | Died from septic shock complications | 24 | 24 | 24 |
| 63 | F | None | Shortness of breath, cough, and sputum production | Hypoxemia 50% on RA, leukocytosis 19.3 k/mcl, lymphopenia 6%, ferritin 915 ng/mL, D-dimer 3.92 mg/L, procalcitonin 0.6 ng/mL | Chest X-ray-bilateral patchy consolidations | Urine antigen for S. pneumonia-positive | ICU complicated by DVT | Remdesivir, dexamethasone, tocilizumab, ceftriaxone for pneumonia, and Lovenox for DVT | Discharged home after 3 weeks | 25 | 9 | 0 |
| 64 | F | HTN | Fever, cough, sob, hypoxia | Normal WBC, ferritin 380 ng/mL, D-dimer 3.494 | Chest X-ray-bilateral consolidations | Urine antigen for S. pneumoniae-positive | ICU | Remdesivir and dexamethasone for COVID-19. 7-day course of cefepime for pneumonia. ARDS-lung protective ventilation, paralytics, and nitric oxide | Discharge to subacute rehab after extubation to nasal cannula | 24 | 20 | 19 |
| 87 | F | HTN, HLD, DM, breast cancer on letrozole and diverticulosis | AMS, sob, hypoxia | WBC 9.9 k/mcl, D-dimer 2.23 mg/L, procalcitonin of 6.84 ng/mL | CT-bilateral patchy GG infiltrates | Sputum cultures-S. pneumonia | ICU | Remdesivir and dexamethasone for COVID-19. Ceftriaxone for S. pneumonia | Extubated→respiratory failure→reintubated. Tracheostomy and feeding tube and transferred to rehab | 34 | 34 | 34 |